TOKYO -- Japanese drugmaker Shionogi plans to increase production capacity for its coronavirus vaccine candidate, aiming to turn out enough vaccines for 30 million people per year by the end of 2021, as competition intensifies to develop COVID-19 treatments, Nikkei has learned.
Shionogi will increase capacity at its plant by more than tripling its previous capacity by adding manufacturing equipment. It plans to carry out all phases of production, including procurement of materials, in Japan.
